Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Clinical trial NCT05470491 · RECRUITING
Trial details
- NCT number
- NCT05470491
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-26
- Primary completion
- 2027-07-30
- Enrollment
- 265
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.